Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

BRAF V600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia

Yo-Ting Tsai, MS, Aparna Lakshmanan, PhD, Amy M. Lehman, MAS, Ellen J. Sass, Minh Tran, Fabienne McClanahan, MD PhD, Meixiao Long, MD PhD, Bonnie K. Harrington, DVM, Krista La Perle, DVM, PhD, Vincenzo Coppola, MD, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD, Michael R. Grever, MD, David M. Lucas, PhD

Blood (2016) 128 (22): 1206.

https://doi.org/10.1182/blood.V128.22.1206.1206

Published: 2016

Journal Articles

Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo

Fabienne McClanahan, MD PhD, Sean D. Reiff, Daphne Guinn, PhD, Minh Tran, Larry Beaver, Samantha McWorther, Rose Mantel, Lisa L. Smith, MS, Amy J. Johnson, PhD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 352.

https://doi.org/10.1182/blood.V128.22.352.352

Published: 2016

Journal Articles

REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK

Blood (2016) 128 (22): 4399.

https://doi.org/10.1182/blood.V128.22.4399.4399

Published: 2016

Journal Articles

Minimal Renal Toxicity after Rituximab DHAP with a Modified Cisplatin Application Scheme in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Katharina Lisenko, MD, Fabienne McClanahan, MD PhD, Tilman Schöning, MD, Mark-Alexander Schwarzbich, MD, Martin Cremer, MD, Tobias Dittrich, MD, Anthony D. Ho, MD, Mathias Witzens-Harig, MD

Blood (2015) 126 (23): 1506.

https://doi.org/10.1182/blood.V126.23.1506.1506

Published: 2015

Journal Articles

The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in Eµ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling

Claudia Dürr, Bola Hanna, Fabienne McClanahan, MD, Andrew James Clear, BSc, Thorsten Zenz, MD, Stephan Stilgenbauer, MD, John G. Gribben, MD DSc, Peter Lichter, PhD, Martina Seiffert, PhD

Blood (2014) 124 (21): 1966.

https://doi.org/10.1182/blood.V124.21.1966.1966

Published: 2014

Journal Articles

Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model

Bola Hanna, Fabienne McClanahan, MD, Nadja Zaborsky, PhD, Claudia Dürr, Verena Kalter, Alexander Egle, MD, John G. Gribben, MD DSc, Peter Lichter, PhD, Martina Seiffert, PhD

Blood (2014) 124 (21): 3298.

https://doi.org/10.1182/blood.V124.21.3298.3298

Published: 2014

Journal Articles

Aberrant PD-L1 Expression in CLL As a Result of Adaptive Immune Resistance Mediated By Tumor-Secreted Circulating miRNA Binding to Toll-like Receptor 7

Fabienne McClanahan, MD, Federica Calore, PhD, Nicola Zanesi, PhD, John G. Gribben, MD DSc, Carlo M. Croce, MD

Blood (2014) 124 (21): 716.

https://doi.org/10.1182/blood.V124.21.716.716

Published: 2014

Journal Articles

Immune Checkpoint Blockade with Anti-PD-L1 Prevents Immune Dysfuntion and CLL Development in the TCL1 Adoptive Transfer Mouse Model

Bola Hanna, Fabienne McClanahan, MD, Andrew James Clear, BSc, Shaun Miller, Peter Lichter, PhD, Martina Seiffert, PhD, John G. Gribben, MD DSc

Blood (2014) 124 (21): 717.

https://doi.org/10.1182/blood.V124.21.717.717

Published: 2014

Journal Articles

T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 Subsets and This Can Be Further Promoted By Ibrutinib Treatment

Fabienne McClanahan, MD, Shaun Miller, John C. Riches, MD, Essam Ghazaly, MD, PhD, William P. Day, Melania Capasso, PhD, John Gribben, MD, DSc

Blood (2013) 122 (21): 4120.

https://doi.org/10.1182/blood.V122.21.4120.4120

Published: 2013

Journal Articles

NK Cells From CLL Patients Exhibit Down-Regulation Of Interferon Response Genes That Can Be Reversed With Lenalidomide

John C. Riches, MD, Ajanthah Sangaralingam, PhD, Tracy Chaplin, Fabienne McClanahan, MD, Sameena Iqbal, Samir G. Agrawal, Alan G. Ramsay, PhD, John Gribben, MD, DSc

Blood (2013) 122 (21): 4131.

https://doi.org/10.1182/blood.V122.21.4131.4131

Published: 2013

Journal Articles

Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility

Conor J. O'Donovan, Alan G. Ramsay, PhD, Fabienne McClanahan, MD, Laura Rassenti, PhD, Thomas J. Kipps, MD, PhD, John Gribben, MD, DSc, John C. Riches, MD

Blood (2013) 122 (21): 4159.

https://doi.org/10.1182/blood.V122.21.4159.4159

Published: 2013

Journal Articles

Intraclonal Complexity Of CLL Fractions In Cell Proliferation Rates, Gene Expression Signatures, and Responses To Autologous T-Cell Help In Peripheral blood and Secondary Lymphoid Tissues

Shih-Shih Chen, Thomas M. Herndon, MD, Claire Emson, PhD, John C. Riches, MD, Fabienne McClanahan, MD, Timothy Tong, Xiao-Jie Yan, MD PhD, Piers E.M. Patten, MD, PhD, John Gribben, MD, DSc, Adrian Wiestner, MD, PhD, Nicholas Chiorazzi, MD

Blood (2013) 122 (21): 115.

https://doi.org/10.1182/blood.V122.21.115.115

Published: 2013

Journal Articles

Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On Eμ-TCL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo

Fabienne McClanahan, MD, Cristina Ghirelli, PhD, Paul Greaves, MD, John C. Riches, MD, Rita Coutinho, MD, Alan G. Ramsay, PhD, John G Gribben

Blood (2012) 120 (21): 313.

https://doi.org/10.1182/blood.V120.21.313.313

Published: 2012

Journal Articles

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Mathias Witzens-Harig, MD, Axel Benner, Michael Rieger, MD, Fabienne McClanahan, MD, Manfred Hensel, MD, Kai Neben, MD, Peter Dreger, MD, Eva Lengfelder, MD, Ingo Schmidt-Wolf, MD, Alwin Krämer, MD, PhD, Anthony D. Ho, MD

Blood (2011) 118 (21): 3700.

https://doi.org/10.1182/blood.V118.21.3700.3700

Published: 2011

Journal Articles

Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy.

Fabienne McClanahan, MD, Thomas Hielscher, Michael Rieger, MD, Manfred Hensel, MD, PhD, Kai Neben, Jens Hillengass, MD, Klaus Herfarth, MD, PhD, Anthony D. Ho, MD, PhD, Mathias Witzens-Harig, MD

Blood (2009) 114 (22): 2722.

https://doi.org/10.1182/blood.V114.22.2722.2722

Published: 2009

Journal Articles

Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.

Peter Dreger, Hartmut Döhner, Hildegard Greinix, MD, Fabienne McClanahan, MD, Manfred Hensel, Bernd Hertenstein, Ulrich Dührsen, MD, PhD, Markus Hentrich, Lorenz Trümper, Ruth Sonnen, Bertold Emmerich, Wolfgang Ulrich Knauf, Georg Hopfinger, MD, Michael Hallek, Michael Kneba, MD, PhD, Norbert Schmitz, Stephan Stilgenbauer, MD

Blood (2009) 114 (22): 879.

https://doi.org/10.1182/blood.V114.22.879.879

Published: 2009

Journal Articles

How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).

Fabienne McClanahan, MD, Thomas Hielscher, Michael Rieger, MD, Manfred Hensel, MD, PhD, Martin Bentz, MD, Ingo Schmidt-Wolf, Andreas Kaebisch, MD, Hans-Jürgen Salwender, Heinz Dürk, Hans Juergen Staiger, MD, Thomas Mandel, MD, Kai Neben, MD, Jens Hillengass, MD, Anthony D. Ho, MD, PhD, Mathias Witzens-Harig, MD

Blood (2009) 114 (22): 2687.

https://doi.org/10.1182/blood.V114.22.2687.2687

Published: 2009

NARROW

BRAF V600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia

Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo

REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK

Minimal Renal Toxicity after Rituximab DHAP with a Modified Cisplatin Application Scheme in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in Eµ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling

Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model

Aberrant PD-L1 Expression in CLL As a Result of Adaptive Immune Resistance Mediated By Tumor-Secreted Circulating miRNA Binding to Toll-like Receptor 7

Immune Checkpoint Blockade with Anti-PD-L1 Prevents Immune Dysfuntion and CLL Development in the TCL1 Adoptive Transfer Mouse Model

T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 Subsets and This Can Be Further Promoted By Ibrutinib Treatment

NK Cells From CLL Patients Exhibit Down-Regulation Of Interferon Response Genes That Can Be Reversed With Lenalidomide

Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility

Intraclonal Complexity Of CLL Fractions In Cell Proliferation Rates, Gene Expression Signatures, and Responses To Autologous T-Cell Help In Peripheral blood and Secondary Lymphoid Tissues

Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On Eμ-TCL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy.

Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.

How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only